Novel peptide targeting dendritic cells and composition for treating cancer comprising the same

A novel peptide targeting dendritic cells with tumor antigens and flagellin, identified via biopanning, addresses the limitations of current cancer treatments by enhancing dendritic cell activation and immune responses, leading to effective tumor suppression and improved patient survival.

JP2024541794AActive Publication Date: 2024-11-13IND FOUND OF CHONNAM NAT UNIV
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2024513491
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-28
Filing Date
2022-10-26
Publication Date
2024-11-13
Estimated Expiration
2042-10-26

AI Technical Summary

Technical Problem

Existing cancer treatments, including surgery, radiation therapy, and chemotherapy, are inadequate for completely curing cancer, especially metastatic and recurrent cases, and current dendritic cell-based therapies are costly and require individual tailoring, with immature dendritic cells potentially promoting cancer growth.

Method used

Development of a novel peptide that targets dendritic cells in vivo, combined with a tumor antigen and flagellin, to induce potent dendritic cell activation and enhance immune responses, using biopanning to identify peptides with sequences such as SEQ ID NO: 6, SEQ ID NO: 22, and SEQ ID NO: 23, formulated into a pharmaceutical or vaccine composition.

Benefits of technology

The peptide composition induces long-term survival and enhances anti-cancer immune responses, effectively suppressing tumors and improving patient outcomes by activating dendritic cells and modulating immune responses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541794000001_ABST
    Figure 2024541794000001_ABST
Patent Text Reader

Abstract

The present invention relates to a novel peptide targeting dendritic cells in vivo and a composition for cancer treatment comprising the same. Specifically, the present invention relates to a composition for cancer treatment or prevention comprising a novel peptide targeting dendritic cells in vivo, a tumor antigen, and flagellin. In addition, the novel peptide targeting dendritic cells in vivo of the present invention, the tumor antigen, and flagellin may be linked to each other in one peptide, or may be contained in each peptide.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a novel peptide targeting dendritic cells in vivo and a composition for treating cancer comprising the same. Specifically, the present invention relates to a composition for treating or preventing cancer comprising the novel peptide targeting dendritic cells in vivo, a tumor antigen, and flagellin. In addition, the novel peptide targeting dendritic cells in vivo of the present invention, the tumor antigen, and flagellin may be linked together in one peptide or may be contained in each peptide. [Background technology]

[0002] Existing cancer treatment methods include surgery, radiotherapy, and chemotherapy using anticancer drugs, which are used to remove cancer cells as much as possible, and although these methods can be used in a relatively wide range of cancer treatments, they are not fundamental treatments for cancer because they are accompanied by side effects and are difficult to cure completely. In particular, most metastatic and recurrent cancers cannot be treated with surgery and are often resistant to chemical treatments, so the development of new treatments for such cancer patients is urgently needed.

[0003] To overcome the limitations of conventional cancer treatments, active research into anti-cancer immunotherapy has been conducted, and it has recently been approved for clinical use worldwide. Anti-cancer immunotherapy is a method of treating cancer by using the characteristics of immune cells in the body to enhance immune activity against cancer cells or by suppressing the way cancer cells avoid attack by immune cells, and includes immune cell therapy, immune checkpoint inhibitors, therapeutic cancer vaccines, and therapeutic antibodies.

[0004] Therapeutic cancer vaccines include anti-cancer vaccines that use tumor cell lysates or tumor antigens derived from naturally occurring cancer tissues (intact tumour cells) or cancer cell lines, and DC-based cancer vaccines that use autologous dendritic cells (DCs) generated by exposing cancer cell-derived antigens or tumor lysates.

[0005] Recently, cancer therapeutic agents using dendritic cells have been developed, which are more patient-oriented than any other existing therapeutic agents and can show long-term efficacy through memory immunity, and are therefore very effective and safe in preventing metastasis and recurrence of the same cancer. Therefore, they are expected to be a new anti-cancer immunotherapy and are being developed as therapeutic vaccines for various cancers. In particular, dendritic cell cancer vaccines can be used as therapeutic agents to prevent metastasis and recurrence after surgical removal of the primary cancer, and will have considerable competitiveness in the cancer treatment market.

[0006] Dendritic cells (DCs) are antigen-presenting cells of the mammalian immune system, and have membranous or spiny dendritic processes. The main function of dendritic cells is to process antigenic substances and present them to T cells of the immune system. Thus, dendritic cells are the main antigen-labeling cells that activate non-sensitized T lymphocytes, and play the role of messengers between the innate and adaptive immune systems. To date, cancer treatment using the immune system has been proven in numerous animal experiments, and the identification of tumor-specific antigens recognized by human T lymphocytes has promoted the development of immunotherapy.

[0007] Various anti-cancer vaccine strategies targeting dendritic cells have been studied. Some are based on in vitro manipulation of dendritic cells, while others are based on in vivo stimulation of dendritic cells. In the former, dendritic cells are differentiated from blood cells taken from the patient. That is, they are cultured and matured in vitro with tumor antigen peptides, tumor lysates, killed tumor cells, or heat shock proteins extracted from autologous tumors, and finally, they are reinjected into the patient. However, recent research results have shown that using immature dendritic cells as a cell therapy agent can actually result in more activation of the cancer, and there is a problem that fully matured mature dendritic cells must be used. In addition, there is a disadvantage that it is a personalized therapy, which is expensive. In the latter, stimulation of dendritic cells is performed after injecting peptides, proteins, irradiated tumor cells, or other viruses containing antigenic peptides that target dendritic cells into the patient. However, since dendritic cell activation is influenced by the ability to effectively activate cytotoxic T lymphocytes, the degree of dendritic cell activation is judged to be a delicate factor.

[0008] Meanwhile, the unit protein that constitutes the flagellum filament is called flagellin. Flagellins are regularly combined to form filaments, which allow bacteria to move. Flagellins are substances that stimulate pattern recognition receptors, and have been studied as a target for the development of vaccine carrier proteins or vaccine adjuvants. Antigen-flagellin fusion proteins have been proven to be effective as experimental vaccines against various infectious diseases, including pneumonia, West Nile fever, malaria, tuberculosis, and bacterial periodontal disease, and TLR5 activation by flagellin has been reported to protect hematopoietic cells and gastrointestinal tissues from radiation and to affect the survival and growth of cancer cells. In addition, in Korean Patent Registration No. 10-0795839, the present inventors demonstrated that flagellin (FlaB), a component of septicemic Vibrio, acts on Toll-like receptor 5 of host cells to induce a strong immunomodulatory effect, thereby showing the efficacy of an excellent mucosal vaccine adjuvant.

[0009] Therefore, the inventors of the present invention discovered a novel peptide that targets dendritic cells in vivo by biopanning, and developed a recombinant integrated polypeptide vaccine containing the novel peptide that targets dendritic cells, a tumor antigen, and flagellin, thereby completing a composition that has superior effects in cancer treatment. [Prior art documents] [Patent documents]

[0010] [Patent Document 1] Korean Patent No. 10-0795839 [Non-patent literature]

[0011] [Non-Patent Document 1] Lee SE, Kim SY, Jeong BC, Kim YR, Bae SJ, Ahn OS, et al. A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect Immun. 2006;74(1):694-702. Summary of the Invention [Problem to be solved by the invention]

[0012] An object of the present invention is to provide a novel peptide that targets dendritic cells in vivo.

[0013] The present invention aims to provide novel peptides that target dendritic cells, tumor antigens, and peptides for treating or preventing cancer, including flagellin.

[0014] An object of the present invention is to provide a pharmaceutical composition for treating or preventing cancer, comprising a novel peptide that targets dendritic cells in vivo, a tumor antigen and flagellin.

[0015] An object of the present invention is to provide a vaccine composition for treating or preventing cancer, which comprises a novel peptide that targets dendritic cells in vivo, a tumor antigen and flagellin. [Means for solving the problem]

[0016] The present invention provides peptides for treating or preventing cancer that target dendritic cells.

[0017] Also provided is a polynucleotide comprising a nucleic acid sequence encoding the peptide.

[0018] The peptide for treating or preventing cancer that targets dendritic cells may comprise an amino acid sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:11, and preferably, the peptide may comprise any one amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:9, and SEQ ID NO:10. More preferably, the peptide may comprise any one amino acid sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:9, and SEQ ID NO:10, and most preferably, the peptide may comprise the amino acid sequence of SEQ ID NO:6.

[0019] The cancer therapeutic or preventive peptide that targets dendritic cells may be capable of binding to dendritic cells in vivo and inducing their activity.

[0020] The cancer treatment or prevention peptide that targets dendritic cells may further comprise one or more selected from the group consisting of tumor antigens and flagellin, and may comprise four consecutive tumor antigens.

[0021] The tumor antigen may comprise the amino acid sequence of SEQ ID NO:22, and the flagellin may comprise the amino acid sequence of SEQ ID NO:23.

[0022] The cancer therapeutic or preventive peptide targeting dendritic cells may comprise the amino acid sequence of SEQ ID NO:6, the amino acid sequence of SEQ ID NO:22, and the amino acid sequence of SEQ ID NO:23, and preferably the amino acid sequence of SEQ ID NO:25.

[0023] The cancer therapeutic or preventive peptides that target dendritic cells may induce long-term survival and may have immune enhancing effects.

[0024] The present invention also provides a pharmaceutical composition for treating or preventing cancer, comprising the peptide for treating or preventing cancer that targets dendritic cells.

[0025] The present invention also provides a vaccine composition for treating or preventing cancer, comprising the peptide for treating or preventing cancer that targets dendritic cells.

[0026] The pharmaceutical composition or vaccine composition for cancer treatment or prevention, which comprises the cancer treatment or prevention peptide targeting dendritic cells, may further comprise one or more selected from the group consisting of tumor antigens and flagellin, and may comprise four consecutive tumor antigens.

[0027] In the pharmaceutical composition or vaccine composition for treating or preventing cancer, which contains the peptide for treating or preventing cancer that targets dendritic cells, the peptide for targeting dendritic cells, the tumor antigen, and flagellin may be linked together in a single peptide or may be contained in each peptide. Effect of the Invention

[0028] The composition of the present invention, comprising the novel peptide targeting dendritic cells in vivo, a tumor antigen and flagellin, induces strong dendritic cell activation and immune enhancing efficacy, thereby increasing tumor antigen-specific anti-cancer immune responses and having excellent cancer suppression effects. [Brief description of the drawings]

[0029] [Figure 1] FIG. 1 is a diagram showing the general structure of the present invention.

[0030] [Diagram 2] FIG. 1 is a schematic diagram of the in vivo biopanning process in mice.

[0031] [Diagram 3] 1 shows the enrichment and frequency of phagemid particles following rounds of in vivo biopanning in mice.

[0032] [Figure 4] 1 shows the sequences of peptides obtained by a round of in vivo biopanning in mice.

[0033] [Diagram 5]Shown are six peptides selected after two rounds of in vivo biopanning in mice.

[0034] [Figure 6] 1 shows the results of measuring cellular uptake of dendritic cell-targeting peptides of the present invention in bone marrow-derived dendritic cells (BMDCs).

[0035] [Figure 7] 1 shows the results of measuring cellular uptake of dendritic cell-targeting peptides of the present invention in lymph node cells, splenic dendritic cells, and bone marrow-derived dendritic cells (BMDCs).

[0036] [Figure 8] 1 shows the localization of the DCpep6 peptide of the invention in cervical lymph node (cLN) cells by confocal microscopy after administration of the peptide to the mouse nasal cavity.

[0037] [Figure 9] FIG. 1 is a schematic diagram of the peptide components of the present invention.

[0038] [Figure 10] The results of SDS-PAGE and Western blot of FlaB, E7ΔNLS, EF and DEF are shown.

[0039] [Figure 11] The figures show the tumor volume and size in mice treated with E7FL, E7ΔNLS, and FlaB alone and in combination. [Figure 12] The figures show the tumor volume and size in mice treated with E7FL, E7ΔNLS, and FlaB alone and in combination.

[0040] [Figure 13] NF-κB activation levels upon TLR-5 stimulation of FlaB, EF and DEF are shown.

[0041] [Figure 14]The cellular uptake of EF and DEF in bone marrow-derived dendritic cells (BMDCs) was measured by flow cytometry analysis.

[0042] [Figure 15] 1 shows the location of EF and DEF in bone marrow-derived dendritic cells (BMDCs) and Raw264.7 cells by confocal microscopy.

[0043] [Figure 16] The distribution of EF and DEF in vivo in lymph nodes over time is shown.

[0044] [Figure 17] 1 shows the results of measuring cellular uptake of EF and DEF in draining inguinal lymph node (iLN) cells.

[0045] [Figure 18] The survival rates of mice administered E7Pep+F, E7ΔNLS, EF, and DEF are shown. [Figure 19] The survival rate and tumor volume of mice administered E7Pep+F, E7ΔNLS, EF, and DEF are shown.

[0046] [Figure 20] The levels of CD80 and CD86 expression in bone marrow-derived dendritic cells (BMDCs) from EF and DEF are shown.

[0047] [Figure 21] 1 shows the results of measuring tetramer-positive cells selective for the E7-CTL epitope in peripheral blood CD8+ cells of mice administered E7ΔNLS, EF, and DEF. [Figure 22] 1 shows the results of measuring tetramer-positive cells selective for the E7-CTL epitope in peripheral blood CD8+ cells of mice administered E7ΔNLS, EF, and DEF.

[0048] [Diagram 23]The figures show the results of measuring IFN-γ-secreting cells in the spleens or tumor lymph nodes of mice administered E7ΔNLS, EF, and DEF. [Figure 24] The figures show the results of measuring IFN-γ-secreting cells in the spleens or tumor lymph nodes of mice administered E7ΔNLS, EF, and DEF.

[0049] [Diagram 25] The survival rates and tumor volumes of wild-type (WT), TLR5-deficient (TLR5- / -), and NLRC4-deficient (NLRC4- / -) mice treated with EF and DEF are shown.

[0050] [Figure 26] The mitotic index of CD8+ T cells in wild-type (WT) and NLRC4-deficient (NLRC4- / -) mice treated with EF and DEF is shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0051] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, the present application will be described in detail with reference to the accompanying drawings so that those skilled in the art can easily carry out the present invention. However, the present application may be embodied in various forms and is not limited to the embodiments and examples described herein.

[0052] Throughout this specification, when a part "comprises" a certain element, this does not mean that other elements are excluded, but that other elements may also be included, unless otherwise specified.

[0053] The present invention provides novel peptides that target dendritic cells in vivo, which were discovered by biopanning.

[0054] The novel peptide targeting dendritic cells in vivo has excellent ability to target dendritic cells isolated from the spleen and lymph nodes, and various dendritic cells induced from bone marrow, and can effectively activate dendritic cells in vivo.

[0055] In one embodiment, the novel peptide targeting in vivo dendritic cells of the present invention may comprise the amino acid sequences of SEQ ID NO:1 to SEQ ID NO:11, and preferably the amino acid sequences of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:9, and SEQ ID NO:10. More preferably, the novel peptide may comprise the amino acid sequences of SEQ ID NO:6, SEQ ID NO:9, and SEQ ID NO:10, and most preferably the amino acid sequence of SEQ ID NO:6.

[0056] In the present invention, "biopanning" refers to a technique for selecting peptides having affinity for a given target from a peptide library constructed by various display technologies such as phage display, bacterial display, mRNA display, ribosome display, yeast display, etc.

[0057] The "dendritic cell (DC)" of the present invention is a specialized antigen-presenting cell that plays a central role in linking innate and adaptive immune responses by regulating the activation and differentiation of T cells through interaction with T cell receptors via major histocompatibility complex (MHC) / peptide complexes. It is known that dendritic cells are CD14 positive when derived from human peripheral circulating blood, and become positive for CD11c and CD68 cell-representing factors as they differentiate into dendritic cells.

[0058] In the present invention, "CD11c" refers to a member of the integrin CD18 family, which forms a heterodimer in the form of CD11c / CD18 and is involved in phagocytosis as complement receptor 4. Human CD11c is known to be expressed mainly in the plasma membrane of monocytes, macrophages, natural killer cells, and most dendritic cells, but in mice, it is almost exclusively expressed in dendritic cells and is known as the best marker for dendritic cells.

[0059] The present invention provides peptides for treating or preventing cancer that target dendritic cells.

[0060] Also provided is a polynucleotide comprising a nucleic acid sequence encoding the peptide.

[0061] In one embodiment, the peptide may comprise an amino acid sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:11, and preferably, the peptide may comprise any one amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:9, and SEQ ID NO:10. More preferably, the peptide may comprise any one amino acid sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:9, and SEQ ID NO:10, and most preferably, the peptide may comprise the amino acid sequence of SEQ ID NO:6.

[0062] The peptide can bind to dendritic cells in vivo and induce their activity.

[0063] The cancer treatment or prevention peptide that targets dendritic cells may further include one or more selected from the group consisting of tumor antigens and flagellin.

[0064] In one embodiment, the peptide may comprise the amino acid sequence of SEQ ID NO:6, the amino acid sequence of SEQ ID NO:22, and the amino acid sequence of SEQ ID NO:23.

[0065] In one embodiment, the peptide may comprise four consecutive amino acid sequences of SEQ ID NO: 22, and preferably comprises the amino acid sequence of SEQ ID NO: 25 (DCpep6-4xE7ΔNLS-FlaB).

[0066] The amino acid sequence of SEQ ID NO: 22 represents a tumor antigen, which is a tumor-specific antigen expressed only in tumor cells, and may be a mutated protein, a tumor-specific oncogene, or a viral oncogene.

[0067] In one embodiment, the tumor antigen is HPV16E7 (E7 FL ) from which the N-terminal nuclear localization sequence (NLS) has been deleted.

[0068] The amino acid sequence of SEQ ID NO: 23 represents flagellin B (FlaB) derived from Vibrio vunigicus, and flagellin is a major protein that constitutes the filament of bacterial flagella, and when a flagellated bacterium is infected, it can induce an immune response in an infected host. Specifically, Toll-like receptor 5 (TLR5) present on the surface of the cell membrane of the human body induces intracellular signaling by interacting with the flagellin, thereby increasing the expression of the transcription factor NF-κB, which can induce innate immune signal activation as well as regulate adaptive immune responses. In addition, NAIP (NLR family, apoptosis inhibitory protein) present in the cells of the human body induces NLRC4 (NLR containing a caspase activating and recruitment domain protein 4) inflammasome activation by interacting with the flagellin, which increases the expression of the transcription factor NF-κB, which can induce innate immune signal activation as well as regulate adaptive immune responses.

[0069] In one embodiment, the flagellin is flagellin B (FlaB) derived from Vibrio vunigicus and may be prepared by the method disclosed in Korean Patent Registration No. 10-0795839, the entire contents of which are incorporated by reference into the present invention.

[0070] The present invention provides a pharmaceutical composition for treating or preventing cancer, comprising a peptide for treating or preventing cancer that targets dendritic cells in the body.

[0071] The present invention also provides a vaccine composition for treating or preventing cancer, comprising a peptide for treating or preventing cancer that targets dendritic cells in the body.

[0072] The pharmaceutical composition or vaccine composition for treating or preventing cancer, comprising the peptide for treating or preventing cancer that targets dendritic cells, may further comprise at least one selected from the group consisting of a tumor antigen and flagellin.

[0073] In the pharmaceutical composition or vaccine composition for treating or preventing cancer, which contains the peptide for treating or preventing cancer that targets dendritic cells, the peptide for targeting dendritic cells, the tumor antigen, and flagellin may be linked together in a single peptide or may be contained in each peptide.

[0074] In one embodiment, the pharmaceutical or vaccine composition may comprise a peptide comprising the amino acid sequence of SEQ ID NO:6, the amino acid sequence of SEQ ID NO:22, and the amino acid sequence of SEQ ID NO:23, or may comprise a peptide comprising the amino acid sequence of SEQ ID NO:6, a peptide having the amino acid sequence of SEQ ID NO:22, and a peptide comprising the amino acid sequence of SEQ ID NO:23, respectively.

[0075] In one embodiment, the peptide may comprise four consecutive amino acid sequences of SEQ ID NO: 22, and preferably comprises the amino acid sequence of SEQ ID NO: 25 (DCpep6-4xE7ΔNLS-FlaB).

[0076] The pharmaceutical composition or vaccine composition of the present invention contains antigen non-specific and specific immune inducers and can induce a general immune response in vivo and a specific immune response against a specific antigen.

[0077] The pharmaceutical composition or vaccine composition of the present invention can exhibit an antitumor effect.

[0078] The pharmaceutical or vaccine composition of the present invention can exhibit immune enhancing effects.

[0079] The pharmaceutical or vaccine composition of the present invention is capable of inducing long-term survival in a subject to which the composition is administered.

[0080] The term "pharmaceutical composition" used in the present invention means a composition administered for a specific purpose. For the purposes of the present invention, the pharmaceutical composition of the present invention is a composition for treating or preventing cancer, comprising a peptide targeting dendritic cells in vivo, a tumor antigen, and flagellin.

[0081] The term "vaccine" as used in the present invention includes prevention of infection or reinfection by the pathogen, reduction in severity of symptoms or elimination of symptoms caused by the pathogen, or substantial or complete elimination of the pathogen or disease caused by the pathogen, by inducing an immune response against the pathogen in an animal, including a human host. The term "vaccine" as used in the present invention also includes reduction in severity of symptoms of a disease associated with the antigen or elimination of symptoms, or substantial or complete elimination of the disease, by regulating an immune response against a specific antigen in an animal, including a human host. Thus, the "vaccine composition" of the present invention may be administered to an animal, including a human, prophylactically before infection with the pathogen, or therapeutically after infection with the pathogen.

[0082] As used herein, the term "treatment" refers to any action by which the administration of a composition improves or beneficially alters the symptoms of a diseased individual, and "prevention" refers to any action by which the administration of a composition inhibits or delays the onset of a disease.

[0083] According to the present invention, in addition to being able to effectively activate dendritic cells, it is also possible to effectively induce tumor cell-specific immunity, thereby inducing significantly improved anti-cancer immunity.

[0084] The present invention will be described in more detail below using examples. However, the following examples are merely for the purpose of illustration and are not intended to limit the scope of the present invention.

[0085] [Example 1] In vivo biopanning to discover dendritic cell-targeting peptides As shown in FIG. 2, the present invention was carried out as follows to discover peptides that target in vivo dendritic cells (DCs).

[0086] For in vivo biopanning, 10 μl of the CPL3 peptide phagemid library (10 12 pfu / ml) were injected into each nostril of Balb / c mice. Library phages were injected into three mice. Six hours after in vivo panning, mice were euthanized and cervical lymph nodes (cLNs) were harvested. The harvested cLNs were centrifuged and washed three or more times with 0.2% PBST, and then washed once with 100 μl of 0.2 M glycine-HCl buffer, pH 2.2. The cLNs were then incubated in the same buffer at room temperature for 10 min, and the glycine buffer was replaced with cold 1x PBS. The capsules of the cLNs were lightly crushed, and the cell suspension was passed through a 40 μm cell strainer (Falcon, 352340). The resulting single cell suspension was centrifuged and treated with glycine buffer for 5 min, after which the cells were washed with PBS and suspended in MACS buffer.

[0087] The cell suspension contains CD11c +DCs were labeled with MicroBeads MACS (Miltenyi Biotec, 130-052-001) and purified by applying a magnetic field according to the manufacturer's recommendations. After placing the purified DCs in glycine buffer for another 5 min, the cells were washed three more times with PBST (1x PBS + 0.05% Tween 20). They were then suspended in 100 μl glycine buffer and disrupted by five freeze-thaw cycles using high-speed centrifugation (13000 rpm, 10 min) to elute the intracellular phages. Cell disruption was confirmed by trypan blue staining. At the end of the cycles, the glycine buffer was neutralized by adding an equal volume of 1x PBS (pH 7.5). Finally, the preparation was centrifuged and the supernatant containing the eluted phages was collected and stored at -20 °C. The phage titer of the preparation was determined by standard protocols. Individual bacterial clones containing the phagemids were cultured at OD in Luria Broth containing ampicillin (200 μg / ml). 600 The culture was incubated until the value reached 0.5. Identical volumes of all 45 bacterial clones were mixed together for 13 h, and the phages were eluted with M13KO7 helper phage and then amplified in E. coli TG1. Phages from the cell-free supernatant were collected by PEG / NaCl precipitation (4°C / o / n). In a similar manner to the above (1st round), phages amplified in the 1st round were used for the 2nd round of panning, and the DNA sequences of the phages obtained in each round were determined by dideoxy sequencing.

[0088] After the two in vivo biopanning rounds, the phage recovery rates by round were calculated and shown in FIG. 3, and the sequences of peptides obtained by rounds were shown in FIG.

[0089] As shown in Figures 3 and 4, after two rounds of in vivo biopanning, the phage recovery rate increased, the diversity of peptide sequences decreased, and recurrent peptide sequences were identified.

[0090] In addition, from the 50 peptides sequenced in the two rounds, six peptides were selected for multiplexing to test dendritic cell (DC) targeting, as shown in Table 1 below.

[0091] [Table 1]

[0092] To confirm the dendritic cell targeting ability, the peptides need to be visualized, and biotin tagging is required for visualization. Furthermore, a lysine (Lys; K) residue is required for the biotin tagging, but since peptides 1 to 5 do not contain lysine in their amino acid sequences, arginine (Arg; R), which has similar amino acid properties and electrochemical properties to lysine, was substituted with lysine. The six peptides (DCpep 1 to 6) that were finally determined are shown in Table 2 and FIG. 5 below.

[0093] [Table 2]

[0094] [Example 2] Confirmation of targeting efficiency of dendritic cell targeting peptides To confirm the dendritic cell (DC) targeting efficiency of the six peptides determined in Example 1 above, the following procedure was performed.

[0095] The femurs and tibias of C57BL / 6 mice were flushed to isolate bone marrow cells, and red blood cells (RBCs) were removed by ACK lysis (Gibco, A10492-01). The cells were centrifuged, filtered through a 70 μm filter, and suspended in RPMI 1640 medium supplemented with 10% heat-inactivated FBS, 100 units / ml penicillin, and 100 μg / ml streptomycin. The cells were suspended in RPMI 1640 culture medium containing GM-CSF (10 ng / mL; R&D systems, 415-ML-010) and IL-4 (10 ng / mL; R&D systems, 415-ML-010), seeded on cell culture dishes, and cultured at 37°C and 5% CO2. The culture medium was replaced with a new one every 2 days. On days 7–8, dendritic cells (DCs) that were weakly attached to the bottom were collected by gentle pipetting to prepare bone marrow-derived dendritic cells (BMDCs). Splenic dendritic cells were cultured using CD11 + Prepared by MicroBeads MACS (Miltenyi Biotec, 130-052-001).

[0096] The peptides were synthesized using 9-fluorenylmethyoxycarbonyl chemistry, purified to 95% purity using high-pressure liquid chromatography, and biotinylated at the side chain (Anygen Inc., Korea). The peptides were dissolved in an appropriate solvent at a concentration of 0.5 mg / ml. The synthesized peptides were then injected into dendritic cells (CD11c + To test targeting, cervical lymph node (cLN) cells, splenic dendritic cells, and bone marrow derived dendritic cells (BMDCs) were treated with the six peptides in RPMI1640 medium and cultured for 2 hours. After incubation, the cells were harvested, washed, and stained with anti-mouse CD11 + Dendritic cells (CD11c) were stained with APC-conjugated antibody (eBioscience, Clone: ​​N418, 170114-82) or streptavidin-AF488 using FACS. + ) population was analyzed, and the results are shown in Figures 6 and 7.

[0097] As shown in FIG. 6, the cellular uptake of peptides was measured from bone marrow-derived dendritic cells. The targeting ability of DCpep1, 2, and 5 was similar to that of the negative control group, whereas DCpep3, 4, and 6 were CD11c + -BMDCs were efficiently targeted, with the DCpep6 peptide showing particularly high levels.

[0098] Furthermore, as shown in Figure 7, the three peptides (DCpep 3, 4, and 6) exhibiting excellent efficacy were increased in all of cervical lymph node cells, splenic dendritic cells, and bone marrow-derived dendritic cells. In particular, the DCpep6 peptide (SEQ ID NO: 6) showed a significantly high value.

[0099] Therefore, it was confirmed that DCpep3, DCpep4 and DCpep6 peptides among the dendritic cell targeting peptides of the present invention discovered by biopanning exhibit excellent targeting efficiency, and in particular, DCpep6 peptide (SEQ ID NO: 6) has the highest targeting efficiency and targets both dendritic cells isolated from lymph nodes and spleens and dendritic cells induced from bone marrow.

[0100] [Example 3] Confirmation of targeting ability of dendritic cell targeting peptides In order to confirm the targeting ability of the DCpep6 peptide selected in Example 2 to dendritic cells in vivo, the following procedure was carried out.

[0101] BALB / c mice were intranasally administered appropriate concentrations of peptides in a total volume of 10 μl / nostril. A scrambled peptide, previously non-specifically expressed on dendritic cells, was used as a negative control. 6.5 h after inoculation, mice were sacrificed and cervical lymph nodes (cLNs) were harvested. Single cell suspensions were prepared by gently breaking the capsule of the cLNs. After gentle washing with 1x PBS, cells were incubated with anti-mouse CD11 + The cells were stained with APC-conjugated antibody (eBioscience, Clone: ​​N418, 170114-82) or streptavidin-AF488 and analyzed using FACS.

[0102] As shown in FIG. 8, compared with the negative control group, the DCpep6 peptide of the present invention suppressed the expression of CD11c in cervical lymph nodes. + It was found to be clearly localized in the cytoplasm of the cells. Therefore, the DCpep6 peptide (SEQ ID NO: 6) of the present invention isolated by biopanning was found to be specifically localized in the cytoplasm of the cells. + ) targeting ability was confirmed.

[0103] [Example 4] Peptide Production As shown in Table 3 and FIG. 9 below, HPV16E7 lacking the N-terminal nuclear localization sequence (NLS) was used to eliminate the possibility of oncogenesis caused by HPV16E7 (E7 FL To produce the mutant E7NLS peptide, a pET30a+ plasmid (Novagen, 69909-Merck Millipore) was constructed containing a DNA fragment corresponding to a truncated E7. The inserted DNA fragment was amplified by PCR using a codon-optimized DNA template and primers of SEQ ID NO:14 and SEQ ID NO:15.

[0104] FlaB from Vibrio vunigicus was produced by the method disclosed in Lee SE, et al. A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect Immun. 2006; 74(1):694-702.

[0105] To produce the peptide 4xE7ΔNLS-FlaB(EF), first, the synthesized 4xE7ΔNLS DNA fragment (NdeI-E7ΔNLS-EcoRI-E7ΔNLS-SalI-E7ΔNLS-SalI-E7ΔNLS-HindIII) was cloned into pET30a+ plasmid with overhangs recognized by specific restriction enzymes (RE) of NdeI and HindIII. Then, the DNA fragment of FlaB was generated by PCR using primers of SEQ ID NO: 18 and 19 with HindIII and XhoI overhangs, respectively. The DNA fragment of FlaB was digested by HindIII and XhoI restriction enzymes and fused to the C-terminus of 4xE7ΔNLS to generate pET30a+::4xE7ΔNLS::FlaB.

[0106] To generate the peptide DCpep6-4xE7ΔNLS-FlaB(DEF), the DNA fragment of 3xE7ΔNLS::FlaB was extracted from pET30a+::4xE7ΔNLS::FlaB using EcoRI-XhoI restriction enzymes and cloned into pET30a+ plasmid to generate pET30a+::3xE7ΔNLS::FlaB. Next, the DNA fragment of the synthesized DCpep6-E7ΔNLS (NdeI-DCpep6-E7ΔNLS-EcoRI) was amplified by PCR using primers of SEQ ID NO: 16 and SEQ ID NO: 20 with NdeI and EcoRI overhangs, respectively, and cloned into the N-terminus of pET30a+::3xE7ΔNLS::FlaB to generate pET30a+::DCpep6::4xE7ΔNLS::FlaB.

[0107] The DNA sequence of the expression vector was confirmed by dideoxy-chain termination sequencing using the Macrogen Online Sequencing Order System (http: / / dna.macrogen.com / kor / ). The resulting plasmid was transformed into competent E. coli BL21 cells. Protein expression was induced by treating with 0.2 mM IPTG (isopropyl-β-D-thiogalactoside) and growing at 20°C for 18 h, and the cells were pelleted by centrifugation and stored at -80°C. The bacterial cell pellet was lysed in 50 ml of lysis buffer (pH 8; 50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, 0.1% Triton X-100, 0.1% Tween, and 20 μM phenylmethylsulfonyl fluoride). After centrifugation at 18,000 rpm for 30 min, the cell-free supernatant was loaded onto a column containing Ni-NTA agarose beads (Qiagen, Hilden, Germany) according to the manufacturer's instructions.

[0108] The purity of the recombinant peptides was confirmed by SDS-PAGE and Western blot using anti-E7 or anti-FlaB antibodies generated from BALB / c mice, and the results are shown in Figure 10. Lipid polysaccharide (LPS) contamination was removed using TritonX-114 (Sigma-Aldrich, St. Louis, MO), and the remaining TritonX-114 residue was removed using Bio-Beads® SM-2 (Bio-Rad Laboratories, Inc., Hercules, CA) following the manufacturer's guidelines by incubation with 0.3 g of Bio-beads®-2 per ml of protein. Residual LPS content was determined using a gel-clotting Endosafe LAL kit (Charles River, Charleston, SC). LPS levels in protein preparations were maintained below FDA guidelines (less than 0.15 EU / 30 g per mouse).

[0109] [Table 3]

[0110] E7 produced by the above method FL The peptide sequences of E7ΔNLS(E), FlaB(F), 4xE7ΔNLS::FlaB(EF) and DCpep6::4xE7ΔNLS::FlaB(DEF) are shown in Table 4 below.

[0111] [Table 4]

[0112] [Example 5] Tumor antigen efficacy evaluation of E7ΔNLS Seven to eight-week-old female SPF C57BL / 6 mice were purchased from ORIENT (Seongnam-si, Kyunggi-do), and TC-1 cells were cultured in RPMI1640 medium supplemented with 10% heat-inactivated FBS, 100 units / ml penicillin, and 100 μg / ml streptomycin at 37°C and 5% CO2. Tumors were implanted in the center of the right flank of each mouse, with 5 × 10 4 TC-1 cells were subcutaneously injected to establish tumors. When tumor diameter reached 3–5 mm, tumor-bearing mice were randomized and, after anesthesia, were injected with 200 μl PBS, 4 μg FlaB(F), 10 μg E7. FL (E FL ), 10μg E7 FL + 4μg FlaB(E FL E7ΔNLS+4μg FlaB (E+F), 8μg E7ΔNLS, and 8μg E7ΔNLS+4μg FlaB (E+F) were administered three times around the tumor at 5-day intervals. Tumor size was measured at 3-day intervals, and tumor volume was calculated as tumor volume (V) = (tumor length) × (tumor width) × (tumor height) / 2.

[0113] As shown in Fig. 11 and Fig. 12, the antitumor activity of E7ΔNLS(E) and E7 FL (E FL ) induced tumor suppression at similar levels, whereas flagellin (F)-reinforced E7ΔNLS+FlaB (E+F) and E7 FL+FlaB(E FL +F) was found to induce tumor suppression at a superior level, whereas flagellin (F) administration alone was not able to suppress tumor growth.

[0114] Therefore, it was confirmed that the E7ΔNLS peptide of the present invention is an optimal tumor antigen, and that flagellin (FlaB) can enhance antigen-mediated tumor suppression.

[0115] [Example 6] Evaluation of peptides' TLR5 activation ability The TLR5-dependent NF-κB stimulatory activity of 4xE7ΔNLS::FlaB(EF) and DCpep6::4xE7ΔNLS::FlaB(DEF) was measured using HEK-Blue® hTLR5 cells (InvivoGen, hκb-htlr-5) and the HEK-Blue® detection (InvivoGen, hb-det2) analysis system. 50 was calculated using triplicate OD 620 nm values ​​for each protein concentration over a wide range of protein concentrations (AAT Bioquest website, 0.0375 nM to 19.29 nM).

[0116] As shown in Figure 13, the activity level of NF-κB was measured, and it was confirmed that 4xE7ΔNLS::FlaB(EF) and DCpep6::4xE7ΔNLS::FlaB(DEF) increased the activity in a dose-dependent manner, and induced TLR5 stimulating activity. 50 The EC of FlaB was 0.38 nM and 0.32 nM, respectively. 50(0.73 nM), indicating that the 4xE7ΔNLS::FlaB(EF) and DCpep6::4xE7ΔNLS::FlaB(DEF) of the present invention stabilize the TLR5 binding motif without interfering with TLR5 binding activity. Furthermore, it can be seen that DCpep6::4xE7ΔNLS::FlaB(DEF) shows a more excellent effect than 4xE7ΔNLS::FlaB(EF).

[0117] Therefore, it was confirmed that DCpep6::4xE7ΔNLS::FlaB(DEF) of the present invention stably maintains biological activity despite structurally or functionally containing other peptides.

[0118] [Example 7] Peptide dendritic cells (CD11 + ) Target Capability Evaluation Bone marrow-derived dendritic cells (BMDCs) prepared in the same manner as in Example 2 above were treated with various concentrations of 4xE7ΔNLS::FlaB (EF) and DCpep6::4xE7ΔNLS::FlaB (DEF) in RMPI1640 medium and cultured for 2 hours. Cells treated with PBS alone were used as a negative control. After culture, the cells were washed twice with cold 1x PBS containing 3% FBS and then incubated with anti-mouse CD11c + The cells were stained with anti-FlaB antibody (eBioscience, Clone:N418, 25-0114-82) for 1 h at 4 °C and fixed with 4% paraformaldehyde (T&I, BPP-9004) for 10 min at room temperature. The cells were permeabilized using a permeabilization kit according to the manufacturer's instructions (Invitrogen, 00-8333-56), then stained with anti-FlaB antibody and analyzed for dendritic cells (CD11c) using FACS. + ) population was analyzed, and the results are shown in Figure 14.

[0119] BMDCs or Raw264.7 cells were treated with 20 μg / ml of 4xE7ΔNLS::FlaB(EF) and DCpep6::4xE7ΔNLS::FlaB(DEF) in RMPI1640 medium and cultured for 2 hours. After culture, the cells were harvested, washed, fixed with 100% methanol at room temperature for 15 minutes, and then stained with anti-mouse CD11. + The cells were stained with APC-conjugated antibodies and DAPI to stain the nuclei at room temperature for 1 hour. After washing twice with cold 1x PBS, the cells were stained with dendritic cells (CD11c) using a confocal microscope. + The results are shown in Figure 15.

[0120] As shown in Figure 14, the cellular uptake of 4xE7ΔNLS::FlaB(EF) and DCpep6::4xE7ΔNLS::FlaB(DEF) was measured in bone marrow-derived dendritic cells. The results showed that DCpep6::4xE7ΔNLS::FlaB(DEF) showed cellular uptake in a concentration-dependent manner, whereas 4xE7ΔNLS::FlaB(EF) showed little uptake.

[0121] In addition, as shown in Figure 15, DCpep6::4xE7ΔNLS::FlaB(DEF) expresses CD11c + It was found to be located in the cytoplasm of the cells and accumulated in a punctuated pattern.

[0122] Therefore, the DCpep6::4xE7ΔNLS::FlaB(DEF) of the present invention contains a dendritic cell targeting peptide (DCpep6), and thus is an excellent target for dendritic cells (CD11c + ) targeting ability.

[0123] [Example 8] Confirmation of peptide biodistribution Purified 4xE7ΔNLS::FlaB (EF) and DCpep6::4xE7ΔNLS::FlaB (DEF) were mixed with FNR675-NHS ester (BioActs, Korea) at 4°C and kept overnight in the dark with stirring. Labeled EF-FNR675 or DEF-FNR675 was separated from unconjugated dye using a centrifugal filter (10 kDa cutoff) (Amicon Ultra -4, UFC801024) and then washed with PBS. The amount of conjugated protein was then determined from a standard curve of FNR675-NHS ester using a UV-Vis spectrophotometer (UV-2700, Shimadzu, Japan).

[0124] PBS, 50 μg EF-FNR675, and 50 μg DEF-FNR675 were subcutaneously administered to the right inguinal region of C57BL / 6 mice. 1, 6, 12, and 24 hours after administration, the draining inguinal lymph nodes (iLN) were isolated and fluorescent images were determined and shown in Figure 16. In addition, 6 hours after administration, the draining inguinal lymph node (iLN) cells were prepared and dendritic cells (CD11c + ) populations were analyzed to determine dendritic cell targeting in vivo and are shown in FIG.

[0125] As shown in Figure 16, when DEF-FNR675 (DEF) was administered, a fluorescent signal was detected 6 hours after administration, a stronger fluorescent signal was detected 12 hours after administration, and the fluorescent signal was decreased 24 hours after administration. On the other hand, EF-FNR675 (EF) showed a lower fluorescent signal compared to DEF-FNR675 (DEF).

[0126] Furthermore, as shown in FIG. 17, when DEF-FNR675 (DEF) was administered, a higher fluorescent signal was observed, and CD11c was detected 6 hours after administration. + was found to be detectable in cells.

[0127] Therefore, when administered in vivo, the DCpep6::4xE7ΔNLS::FlaB(DEF) of the present invention not only efficiently reaches draining lymph nodes via lymphatic circulation, but also induces dendritic cells (CD11c + It was also found that DEF administered to the body was eliminated from the draining lymph nodes within 24 hours of administration.

[0128] [Example 9] Antitumor efficacy evaluation of peptides The integrated vaccine of the present invention was administered to tumor-bearing mice in the same manner as in Example 5, and the survival rate and tumor volume of the mice were measured. As a positive control group, HPV16 E7 CTL peptide (amino acids 49-57: RAHYNIVTF), known as a cytotoxic T lymphocyte (CTL)-inducing peptide, was administered.

[0129] As shown in Figure 18, the groups administered E7ΔNLS+FlaB (E+F) and DCpep6-4xE7ΔNLS-FlaB (DEF) were found to survive longer than the group administered E7ΔNLS (E), and in particular, DCpep6-4xE7ΔNLS-FlaB (DEF) was found to maintain the longest survival. In addition, it showed a significantly longer survival than the group administered HPV16 E7 CTL peptide + FlaB (E7Pep+F).

[0130] Furthermore, as shown in Figure 19, the tumor volume was the smallest when DCpep6-4xE7ΔNLS-FlaB (DEF) was administered, and the volume was significantly smaller than that of the group administered HPV16 E7 CTL peptide + FlaB (E7Pep+F).

[0131] Therefore, it was confirmed that DCpep6::4xE7ΔNLS::FlaB(DEF) of the present invention has excellent in vivo antitumor efficacy and can maintain long-term survival. In addition, it was confirmed that the peptide of the present invention, which contains a peptide targeting dendritic cells in vivo (DCpep6), a tumor antigen (E7ΔNLS) and flagellin (FlaB), has a superior antitumor efficacy compared to a peptide containing only a tumor antigen and flagellin.

[0132] [Example 10] Immune response evaluation of peptides

[0133] 10-1. Antigen presenting cell activation

[0134] Bone marrow-derived dendritic cells (BMDCs) prepared by the same method as in Example 2 above were treated with PBS, 0.5 μg / ml 4xE7ΔNLS::FlaB (EF) and 0.5 μg / ml DCpep6::4xE7ΔNLS::FlaB (DEF) for 24 hours, then stained with fluorescently labeled antibodies on ice and analyzed by flow cytometry.

[0135] As shown in Figure 20, CD80 and CD86 expression on the surface of BMDCs was measured and it was found that DCpep6::4xE7ΔNLS::FlaB(DEF) enhanced the expression of CD80 and CD86, whereas 4xE7ΔNLS::FlaB(EF) did not induce any statistically significant changes in the expression of CD80 and CD86.

[0136] Therefore, it was confirmed that DCpep6::4xE7ΔNLS::FlaB(DEF) of the present invention activates antigen presenting cells (APCs).

[0137] 10-2. Antigen-specific T cell immune response The peptide of the present invention was administered to tumor-bearing and tumor-free mice in the same manner as in Example 5 above, and peripheral blood was collected from the mice. The blood from which RBCs were removed using an RBC lysis buffer was stained with a tetramer antibody (PE-conjugated HPV16H-2Db-RAHYNIVTF, TB-5008-1, MBL) and a CD8 antibody, and analyzed by flow cytometry.

[0138] As shown in Figure 21, CD8 + Cytotoxic T lymphocyte (CTL) epitope-specific tetramer+ cells were measured from the cells, and the levels were significantly higher in the group administered DCpep6::4xE7ΔNLS::FlaB(DEF) compared to the groups administered PBS, E7ΔNLS(E), and 4xE7ΔNLS::FlaB(EF).

[0139] Furthermore, as shown in FIG. 22, mice not bearing a tumor also showed significantly high levels in the group administered DCpep6::4xE7ΔNLS::FlaB(DEF).

[0140] Therefore, it was confirmed that DCpep6::4xE7ΔNLS::FlaB(DEF) of the present invention effectively induces antigen-specific T cell immune responses.

[0141] 10-3. Cytotoxic T lymphocyte (CTL) peptide-specific immune response

[0142] The peptide of the present invention was administered to tumor-bearing and tumor-free mice in the same manner as in Example 5 above, and single cell suspensions were prepared in the spleen (SPL) or tumor-bearing lymph node (TDLN) of the mice. 6 SPL or 2.5×10 5TDLN cells were plated in 96-well filtration ELISpot plates (Merck, HAMAS4510) and stimulated with 1 μg / ml E7 CTL peptide (amino acids 49-57: RAHYNIVTF). Cells stimulated with 10 ng / ml concanavalin A were used as a positive control. Cells isolated from spleen (SPL) after 2 days of culture or cells isolated from tumor lymph node (TDLN) after 5 days of culture were detected for IFN-γ producing cells using a mouse IFN-γ ELISpot set (BD Bioscience, 551083) according to the manufacturer's guidelines. IFN-γ producing cells (SPOT) were analyzed using a CTL-ImmunoSpot analyzer and ImmunoSpot Professional Software version 5.0 (Cellular Technology, Shaker Heights, OH, USA).

[0143] As shown in Figure 23, IFN-γ-secreting cells were measured in the spleens (SPL) and tumor lymph nodes (TDLN) of tumor-bearing mice, and the levels were significantly higher in the group administered DCpep6::4xE7ΔNLS::FlaB(DEF) compared to the groups administered PBS, E7ΔNLS(E), and 4xE7ΔNLS::FlaB(EF).

[0144] Furthermore, as shown in FIG. 24, mice not bearing a tumor also showed significantly high levels in the group administered DCpep6::4xE7ΔNLS::FlaB(DEF).

[0145] Therefore, it was confirmed that DCpep6::4xE7ΔNLS::FlaB(DEF) of the present invention effectively induces a specific immune response by CTL peptide.

[0146] As a result, it was confirmed that DCpep6::4xE7ΔNLS::FlaB(DEF) of the present invention effectively induces antigen-specific immune responses in vivo, and it is found that the induction of such immune regulatory activity can induce excellent anti-tumor immune responses.

[0147] [Example 11] Signal transduction pathway evaluation of peptide-mediated immune responses Wild type (WT), TLR5-deficient (TLR5 - / - ) and NLRC4 deficiency (NLRC4 - / - ) TC-1 cells were implanted into the center of the right flank of a group of mice, and when the tumor size reached approximately 3-5 mm in diameter, 200 μl of PBS alone, 20 μg of 4xE7ΔNLS::FlaB(EF), and 20 μg of DCpep6::4xE7ΔNLS::FlaB(DEF) were administered around the tumor three times at 5-day intervals. The tumor volume and survival of tumor-bearing mice were measured and shown in Figure 25. Furthermore, preliminary experiments confirmed that TLR5 or NLRC4 deficiency (knockout) did not affect TC-1 tumor growth.

[0148] As shown in Figure 25, TLR5 deficiency (TLR5 - / - ) mice, administration of DCpep6::4xE7ΔNLS::FlaB(DEF) induced significantly longer survival and reduced tumor volume compared to the PBS group, but at a significantly lower level compared to wild-type mice. - / - ) mice, administration of DCpep6::4xE7ΔNLS::FlaB(DEF) did not improve tumor volume or survival time.

[0149] Therefore, the adjuvant function of DCpep6::4xE7ΔNLS::FlaB(DEF) of the present invention, i.e., FlaB(F), was confirmed to act via NLRC4 inflammasome-mediated activation rather than TLR5.

[0150] [Example 12] Peptide-mediated CD8 + T cell activation assessment Bone marrow-derived dendritic cells (BMDCs) prepared by the same method as in Example 2 above were activated with 1 μg / mL of 4xE7ΔNLS::FlaB(EF) and DCpep6::4xE7ΔNLS::FlaB(DEF) for 24 hours. + Spleen cells were prepared using the MagniSort® Mouse CD8 T Cells Enrichment kit (Invitrogen, 8804-6822) according to the manufacturer's instructions and labeled with 5 μM CFSE. EF- or DEF-stimulated BMDCs were cultured at a ratio of 1:5 for 3 days in RPMI1640 medium supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), 1% penicillin / streptomycin (Life Technologies, Grand Island, NY, USA), and 50 mM 2-mercaptoethanol (Sigma, 516732) to produce CFSE-stained CD8 T cells. + Co-cultured with CD8 cells. + T cell proliferation was assessed by CFSE dilution using flow cytometric analysis.

[0151] As shown in FIG. 26, when stimulated with DCpep6::4xE7ΔNLS::FlaB(DEF), CD8 + The mitotic index of T cells was significantly increased, whereas NLRC4 deficiency (NLRC4 - / - ) In mice, however, a decrease was observed.

[0152] Therefore, DCpep6::4xE7ΔNLS::FlaB(DEF) of the present invention inhibits CD8 + We confirmed that it activates T cells, and this is found to be influenced by the NLRC4 inflammasome signaling pathway.

Claims

1. A peptide for treating or preventing cancer, which targets dendritic cells and comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO:

11.

2. The peptide for treating or preventing cancer according to claim 1, characterized in that it comprises any one of the amino acid sequences selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 9 and SEQ ID NO:

10.

3. The peptide for treating or preventing cancer according to claim 1, characterized in that it comprises any one of the amino acid sequences selected from the group consisting of SEQ ID NO:6, SEQ ID NO:9 and SEQ ID NO:

10.

4. The peptide for treating or preventing cancer according to claim 1, characterized in that it comprises the amino acid sequence of SEQ ID NO:

6.

5. The peptide for treating or preventing cancer according to claim 1, which binds to dendritic cells in vivo and induces their activity.

6. The peptide for treating or preventing cancer according to claim 1 , further comprising one or more selected from the group consisting of tumor antigens and flagellin.

7. The peptide for treating or preventing cancer according to claim 6 , which comprises the four tumor antigens in succession.

8. The peptide for treating or preventing cancer according to claim 6 , wherein the tumor antigen comprises the amino acid sequence of SEQ ID NO:

22.

9. The peptide for treating or preventing cancer according to claim 6 , wherein the flagellin comprises the amino acid sequence of SEQ ID NO:

23.

10. The peptide for treating or preventing cancer according to claim 6, characterized in that it comprises the amino acid sequence of SEQ ID NO: 6, the amino acid sequence of SEQ ID NO: 22, and the amino acid sequence of SEQ ID NO:

23.

11. The cancer treating or preventing peptide according to claim 6, comprising the amino acid sequence of SEQ ID NO:

25.

12. The peptide for treating or preventing cancer according to claim 6, which induces long-term survival.

13. The peptide for treating or preventing cancer according to claim 6, which has an immune enhancing effect.

14. A polynucleotide comprising a nucleic acid sequence encoding the peptide of any one of claims 1 to 11.

15. A pharmaceutical composition for treating or preventing cancer, comprising the peptide of claim 1.

16. The pharmaceutical composition for treating or preventing cancer according to claim 15, further comprising at least one selected from the group consisting of a tumor antigen and flagellin.

17. The pharmaceutical composition for treating or preventing cancer according to claim 16, comprising four tumor antigens.

18. The peptide of claim 1, a tumor antigen, and flagellin, The pharmaceutical composition for treating or preventing cancer according to claim 16, wherein the peptide of claim 1, the tumor antigen and flagellin are linked to one peptide or are contained in each peptide.

19. A vaccine composition for treating or preventing cancer, comprising the peptide of claim 1.

20. The vaccine composition for treating or preventing cancer according to claim 19, further comprising at least one selected from the group consisting of a tumor antigen and flagellin.

21. The vaccine composition for treating or preventing cancer according to claim 20, comprising four of the tumor antigens.

22. The peptide of claim 1, a tumor antigen, and flagellin, The vaccine composition for treating or preventing cancer according to claim 20, wherein the peptide of claim 1, the tumor antigen and flagellin are linked to one peptide or are contained in each peptide.

Citation Information

Patent Citations

  • Novel vaccines against hpv and hpv-related diseases

    JP2017507117A

  • Dendritic cell therapeutic agent and immunotherapeutic agent comprising peptide derived from telomerase, and therapeutic methods using the same

    JP2018100243A

  • Novel complex containing cell-permeable peptides, cargo, and TLR peptide agonists for the treatment of glioblastoma

    JP2018510215A

  • Recombinant fusion protein produced by fusing vibrio vulnificus flagellin and pathogenic antigens and the mucosal vaccine containing the same as an active ingredient

    KR1020100114620A

  • Dendritic cell binding proteins and uses thereof

    WO2004092195A2